Top

Journal of Thrombosis and Thrombolysis

Published in:

01-12-2008

Bleeding after antithrombotic therapy in patients with acute ischemic heart disease

Is it the drugs or how we use them?

Authors: Marc Cohen, Karen P. Alexander, Sunil V. Rao

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2008

Abstract

Definitions of bleeding must be considered when evaluating results of clinical trials. Assessments of bleeding impact based on clinical criteria may be more relevant to patient outcomes than those based on simple laboratory measures like an isolated change in hemoglobin, that do not appear to affect patient care. The risk of excessive bleeding in patients who receive antiplatelet and antithrombotic therapy is related to a combination of patient characteristics (older age, female sex, impaired renal function), and delivery factors (excessive dosing, stacking of anticoagulants). Investigators should justify components of bleeding endpoints as being clinically meaningful, sufficiently frequent in the study population, and affected by the intervention.

Rao SV, Jollis JG, Harrington RA et al (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292:1555–1562PubMedCrossRef

Rao SV, O’Grady K, Pieper KS et al (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200–1206PubMedCrossRef

Eikelboom JW, Mehta SR, Anand SS, Xie C et al (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782PubMedCrossRef

Sabatine MS, Cannon CP, Gibson CM et al, for the CLARITY–TIMI 28 Investigators (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189

Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464–1476

Antman EM, Morrow DA, McCabe CH et al, for the ExTRACT-TIMI 25 Investigators (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354:1477–1488

Montalescot G, White HD, Gallo R et al, for the STEEPLE Investigators (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. New Engl J Med 355:1006–1017

Stone GW, McLaurin BT, Cox, DA et al, for the ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203–2216

Moscucci M, Fox KAA, Cannon CP et al, for the GRACE Investigators (2003) Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24:1815–1823

10.

Farouque HM, Tremmel JA, Raissi Shabari F et al (2005) Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. J Am Coll Cardiol 45:363–368PubMedCrossRef

11.

Yang X, Alexander KP, Chen AY et al, for the CRUSADE Investigators (2005) Blood transfusion and non-ST-segment elevation acute coronary syndromes: results from CRUSADE. J Am Coll Cardiol 46:1479–1487

12.

Manoukian SR, Feit F, Mehran R et al (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes, An analysis from the ACUITY Trial. J Am Coll Cardiol 49:1362–1368PubMedCrossRef

13.

Alexander KP, Chen AY, Roe MT et al, for the CRUSADE Investigators (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108–3116

14.

Alexander KP, Chen AY, Newby LK et al, for the CRUSADE Investigators (2006) Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 114:1380–1387

15.

GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682CrossRef

16.

Lincoff AM, Bittl JA, Harrington RA et al, for the REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853–863

17.

Chesebro JH, Knatterud G, Roberts R et al (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142–154PubMed

18.

Ferguson JJ, Califf RM, Antman EM et al, for the SYNERGY Trial Investigators (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45–54

19.

Cohen M, Demers C, Gurfinkel EP et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337:447–452PubMedCrossRef

20.

Peterson ED, Coombs LP, DeLong ER, Haan CK, Ferguson TB (2004) Procedural volume as a marker of quality for CABG surgery. JAMA 291:195–201PubMedCrossRef

21.

The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339:436–443

22.

Boersma E, Harrington RA, Moliterno DJ et al (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359:189–198PubMedCrossRef

23.

Peters RJG, Mehta SR, Fox KAA et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108:1682–1687

24.

Bovill EG, Terrin ML, Stump DC et al (1991) Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 115:256–265PubMed

25.

Rao SV, O’Grady K, Pieper KS et al (2006) A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47:809–816PubMedCrossRef

26.

Majure DT, Aberegg SK (2006) Fondaparinux versus enoxaparin in acute coronary syndromes. N Engl J Med 354:2829; author reply 2830

27.

Fox KAA, Bassand JP, Wallentin L et al (2006) The Efficacy and Safety of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome: Impact of Renal Dysfunction (OASIS 5). ACC 2006, presentation #972-222, presented 13 Mar 2006

28.

Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction— executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 50:652–726CrossRef

29.

Kaul S, Shak PK, Diamond GA (2006) Bivalirudin during early invasive strategy for acute coronary syndromes: noninferiority in ACUITY lies in the eyes of the beholder. Circulation 114:II-552: (abstr 2652)

30.

Kirtane AJ, Piazza G, Murphy SA et al, for the TIMI Study Group (2006) Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47:2374–2379

31.

EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956–961

32.

Smith SC Jr., Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363–2372PubMedCrossRef

33.

EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87–92CrossRef

34.

ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356:2037–2044CrossRef

35.

Bhatt DL, Fox KA, Hacke W, et al, for the CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717

Title: Bleeding after antithrombotic therapy in patients with acute ischemic heart disease
Is it the drugs or how we use them?
Authors: Marc Cohen
Karen P. Alexander
Sunil V. Rao
Publication date: 01-12-2008
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-007-0182-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase

Prevalence of thrombotic risk factors among β-thalassemia patients from Western Iran

Superior vena cava filters: hindsight, insight and foresight

Anticoagulant therapy during cardiopulmonary bypass

Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism

Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials